FrancophonIA/ELRC3.0 huggingface dataset:
English: MARKETING AUTHORISATION NUMBERS EU/1/04/292/009 - carton of 14 tablets
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/04/292/009 - karp 14 tabletiga
English: White to off-white granules in capsules for opening.
Estonian: Valged kuni valkjad graanulid avatavas kapslis
English: During dose titration, serum calcium levels should be monitored frequently, and within 1 week of initiation or dose adjustment of Mimpara.
Estonian: Mimpara annuse tiitrimisel peab sageli ning mitte hiljem kui 1 nädala jooksul pärast ravi alustamist või annuse muutmist mõõtma seerumi kaltsiumisisaldust.
English: NAME OF THE MEDICINAL PRODUCT Mimpara 90 mg film-coated tablets Cinacalcet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 90 mg tablett Cinacalcet
English: MARKETING AUTHORISATION NUMBERS EU/1/04/292/005 - carton of 14 tablets
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/04/292/005 - karp 14 tabletiga
English: • Pre-gelatinised maize starch
Estonian: • Eelželatiniseeritud maisitärklis
English: STATEMENT OF ACTIVE SUBSTANCE Each tablet contains 60 mg of cinacalcet (as hydrochloride).
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 60 mg tsinakaltseeti (vesinikkloriidina).
English: EU/1/04/292/011 - carton of 84 tablets
Estonian: EU/1/04/292/011 - karp 84 tabletiga
English: NAME OF THE MEDICINAL PRODUCT Mimpara 60 mg film-coated tablets Cinacalcet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 60 mg tablett Cinacalcet
English: STATEMENT OF ACTIVE SUBSTANCE Each capsule contains 1 mg of cinacalcet (as hydrochloride).
Estonian: TOIMEAINE(TE) SISALDUS Üks kapsel sisaldab 1 mg tsinakaltseeti (vesinikkloriidina).
English: Mimpara 5 mg granules in capsules for opening
Estonian: Mimpara 5 mg graanulid avatavas kapslis
English: MARKETING AUTHORISATION NUMBERS EU/1/04/292/001 - carton of 14 tablets
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/04/292/001 - karp 14 tabletiga
English: NAME OF THE MEDICINAL PRODUCT Mimpara 30 mg film-coated tablets Cinacalcet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 30 mg tablett Cinacalcet
English: Cinacalcet is not indicated for CKD patients not on dialysis.
Estonian: Dialüüsiravi mittesaavad kroonilise neeruhaigusega patsiendid Tsinakaltseet ei ole näidustatud dialüüsravi mittesaavatele kroonilise neeruhaigusega patsientidele.
English: STATEMENT OF ACTIVE SUBSTANCE Each capsule contains 2.5 mg of cinacalcet (as hydrochloride).
Estonian: TOIMEAINE(TE) SISALDUS Üks kapsel sisaldab 2,5 mg tsinakaltseeti (vesinikkloriidina).
English: Three, 6-month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n = 1,136).
Estonian: Dialüüsravi saavate, terminaalse neerupuudulikkusega patsientidega (n = 1136), kellel oli ravimata sekundaarne hüperparatüreoos, teostati topeltpime-meetodil kolm 6-kuulist platseebokontrolliga uuringut.
English: NAME OF THE MEDICINAL PRODUCT Mimpara 2.5 mg granules in capsules for opening cinacalcet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 2,5 mg graanulid avatavas kapslis tsinakaltseet
English: Parathyroid carcinoma and primary hyperparathyroidism
Estonian: Kõrvalkilpnäärme kartsinoom ja primaarne hüperparatüreoos
English: NAME OF THE MEDICINAL PRODUCT Mimpara 1 mg granules in capsules for opening cinacalcet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 1 mg graanulid avatavas kapslis tsinakaltseet
English: EU/1/04/292/010 - carton of 28 tablets
Estonian: EU/1/04/292/010 - karp 28 tabletiga
English: STATEMENT OF ACTIVE SUBSTANCE Each capsule contains 5 mg of cinacalcet (as hydrochloride).
Estonian: TOIMEAINE(TE) SISALDUS Üks kapsel sisaldab 5 mg tsinakaltseeti (vesinikkloriidina).
English: Mimpara 1 mg granules in capsules for opening Gelatin
Estonian: Mimpara 1 mg graanulid avatavas kapslis Želatiin
English: NAME OF THE MEDICINAL PRODUCT Mimpara 5 mg granules in capsules for opening cinacalcet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 5 mg graanulid avatavas kapslis tsinakaltseet
English: Mimpara 2.5 mg granules in capsules for opening Gelatin
Estonian: Mimpara 2,5 mg graanulid avatavas kapslis Želatiin
English: EU/1/04/292/006 - carton of 28 tablets
Estonian: EU/1/04/292/006 - karp 28 tabletiga
English: Do not initiate cinacalcet or increase the dose if non-compliance is suspected.
Estonian: Kui on kahtlus halvale ravikoostööle, ärge alustage ravi tsinakaltseediga ega suurendage annust.
English: EU/1/04/292/003 - carton of 84 tablets
Estonian: EU/1/04/292/003 - karp 84 tabletiga
English: If you are being treated for secondary hyperparathyroidism The usual starting dose for Mimpara in adults is 30 mg (one tablet) once per day.
Estonian: Mimpara tavaline algannus täiskasvanutel on 30 mg (üks tablett) Mimpara't üks kord ööpäevas.
English: MARKETING AUTHORISATION NUMBER EU/1/04/292/008
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/04/292/008
English: What Mimpara looks like and contents of the pack Mimpara is a light green film-coated tablet.
Estonian: Kuidas Mimpara välja näeb ja pakendi sisu
English: • parathyroid carcinoma.
Estonian: • kolloidne veevaba ränidioksiid.
English: • seizures (convulsions or fits)
Estonian: • krambid (tõmblused),
English: EU/1/04/292/007 - carton of 84 tablets
Estonian: EU/1/04/292/007 - karp 84 tabletiga
English: EU/1/04/292/002 - carton of 28 tablets
Estonian: EU/1/04/292/002 - karp 28 tabletiga
English: The mean (SD) corrected total serum calcium concentrations at baseline were 9.8 (0.6) mg/dL for the cinacalcet + SOC group and 9.8 (0.6) mg/dL for the SOC group.
Estonian: Keskmine (SD) seerumi korrigeeritud kaltsiumisisaldus uuringu alguses oli tsinakaltseedi ja standardravi rühmas 9,8 (0,6) mg/dl ja ainult standardravi rühmas 9,8 (0,6) mg/dl. 25 uuritavale manustati vähemalt üks annus tsinakaltseeti ja tsinakaltseedi keskmine maksimaalne ööpäevane annus oli 0,55 mg/kg/ööpäev.
English: Mimpara 5 mg granules in capsules for opening Gelatin
Estonian: Mimpara 5 mg graanulid avatavas kapslis Želatiin
English: MARKETING AUTHORISATION NUMBER EU/1/04/292/004
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/04/292/004
English: MARKETING AUTHORISATION NUMBER EU/1/04/292/012
Estonian: MÜÜGILOA NUMBER(NUMBRID) EU/1/04/292/012
English: Dyspepsia
Estonian: Düspnoe
English: Closely monitor serum calcium levels (see section 4.2) and patient compliance during treatment with cinacalcet.
Estonian: Seerumi kaltsiumisisaldust ja patsiendi ravikoostööd tuleb ravi ajal tsinakaltseediga hoolega jälgida (vt lõik 4.2).
English: MARKETING AUTHORISATION NUMBER EU/1/04/292/014
Estonian: MÜÜGILOA NUMBER(NUMBRID) EU/1/04/292/014
English: MARKETING AUTHORISATION NUMBER EU/1/04/292/015
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/04/292/015
English: MARKETING AUTHORISATION NUMBER EU/1/04/292/013
Estonian: MÜÜGILOA NUMBER(NUMBRID) EU/1/04/292/013
English: Reduce or withhold dose of Mimpara.
Estonian: Vähendada Mimpara annust või lõpetada manustamine.
English: METHOD AND ROUTE OF ADMINISTRATION For oral use
Estonian: MANUSTAMISVIIS JA -TEE
English: • indigestion (dyspepsia)
Estonian: • kõrvetised (düspepsia),
English: The risk of having seizures is higher if you have had them before;
Estonian: • krampe (tõmblusi või krambihoogusid); krambioht on suurem, kui teil on varem krampe olnud;
English: NAME OF THE MEDICINAL PRODUCT Mimpara 30 mg tablet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 30 mg õhukese polümeerikattega tabletid Tsinakaltseet
English: You should not receive Mimpara together with etelcalcetide.
Estonian: Samaaegne ravi etelkaltsetiidi ja Mimpara'ga ei ole lubatud.
English: NAME OF THE MEDICINAL PRODUCT Mimpara 90 mg tablet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 90 mg õhukese polümeerikattega tabletid Tsinakaltseet
English: No special requirements for disposal.
Estonian: 6.6 Erinõuded ravimpreparaadi hävitamiseks Erinõuded hävitamiseks puuduvad.
English: NAME OF THE MEDICINAL PRODUCT Mimpara 60 mg tablet
Estonian: RAVIMPREPARAADI NIMETUS Mimpara 60 mg õhukese polümeerikattega tabletid Tsinakaltseet
English: • If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures.
Estonian: • teil tekib tuimus või kirvendus suu ümber, lihasvalu, krambid või krambihood; need võivad olla vere madala kaltsiumisisalduse (hüpokaltseemia) ilmingud;
English: Amorphous silicon dioxide
Estonian: Kolloidne veevaba ränidioksiid
English: The full EPAR and risk management plan summary for Ulunar Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Ulunar Breezhaleri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ulunar Breezhaler on 23 April 2014.
Estonian: Euroopa Komisjon andis Ulunar Breezhaleri müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 23. aprillil 2014.
English: However, the CHMP considered that its effects on reducing the rate of exacerbations were too small to recommend use in reducing exacerbations.
Estonian: Komitee järeldas siiski, et ravimi toime ägenemiste sageduse vähenemisel oli liiga vähene, et soovitada seda ägenemiste vähendamiseks.
English: A risk management plan has been developed to ensure that Ulunar Breezhaler is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Ulunar Breezhaleri võimalikult ohutu kasutamine.
English: Ulunar Breezhaler is a medicine that contains two active substances, indacaterol (85 micrograms) and glycopyrronium (43 micrograms).
Estonian: Ulunar Breezhaler on ravim, mis sisaldab kaht toimeainet - indakaterooli (85 mikrogrammi) ja glükopürrooniumi (43 mikrogrammi).
English: What measures are being taken to ensure the safe and effective use of Ulunar Breezhaler?
Estonian: Mis meetmed võetakse, et tagada Ulunar Breezhaleri ohutu ja efektiivne kasutamine?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Ulunar Breezhaler's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Ulunar Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: In both studies, the main measure of effectiveness was how Ulunar Breezhaler improved patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
Estonian: Mõlemas uuringus oli efektiivsuse põhinäitaja see, kuidas Ulunar Breezhaler parandas patsientide forsseeritud ekspiratoorset mahtu (FEV1, suurim õhukogus, mida inimene suudab 1 s jooksul välja hingata) pärast 26-nädalast ravi.
English: The most common side effects with Ulunar Breezhaler (which may affect more than 1 in 10 people) are upper respiratory tract infections (colds).
Estonian: Ulunar Breezhaleri kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on ülemiste hingamisteede nakkused (külmetused).
English: In patients with severely reduced kidney function Ulunar Breezhaler should only be used after a careful benefit-risk assessment.
Estonian: Neerude raske talitlushäirega patsiendid tohivad ravimit Ulunar Breezhaler kasutada ainult pärast kasulikkuse ja riski hoolikat hindamist.
English: The company that makes Ultibro Breezhaler has agreed that its scientific data can be used for Ulunar Breezhaler (‘informed consent').
Estonian: Ultibro Breezhaleri tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Ulunar Breezhaleri toetuseks (teabel põhinev nõusolek).
English: Ulunar Breezhaler has been studied in two main studies involving a total of 2,667 patients with COPD.
Estonian: Ravimit Ulunar Breezhaler uuriti kahes põhiuuringus, kus osales kokku 2667 kroonilise obstruktiivse kopsuhaigusega patsienti.
English: Ulunar Breezhaler also increased FEV1 by 70 ml more than indacaterol alone and 90 ml more than glycopyrronium alone.
Estonian: Ulunar Breezhaler suurendas FEV1 väärtust 70 ml võrra rohkem kui ainult indakaterool ja 90 ml võrra rohkem kui ainult glükopürroonium.
English: Other information about Ulunar Breezhaler
Estonian: Muu teave Ulunar Breezhaleri kohta
English: The effects of Ulunar Breezhaler when used to relieve symptoms of COPD were clinically meaningful.
Estonian: Ulunar Breezhaleri toimed kroonilise obstruktiivse kopsuhaiguse sümptomite leevendamisel olid kliiniliselt olulised.
English: What is Ulunar Breezhaler and what is it used for?
Estonian: Mis on Ulunar Breezhaler ja milleks seda kasutatakse
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ulunar Breezhaler, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Ulunar Breezhaleri omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Ulunar Breezhaler indacaterol / glycopyrronium
Estonian: Ulunar Breezhaler indakaterool/glükopürroonium
English: The first study showed that treatment with Ulunar Breezhaler was more effective than placebo and increased FEV1 by an average of 200 ml more.
Estonian: Esimeses uuringus oli ravi Ulunar Breezhaleriga efektiivsem kui platseeboga ja suurendas FEV1 väärtust keskmiselt 200 ml võrra.
English: This is a summary of the European public assessment report (EPAR) for Ulunar Breezhaler.
Estonian: See on ravimi Ulunar Breezhaler Euroopa avaliku hindamisaruande kokkuvõte.
English: Why is Ulunar Breezhaler approved?
Estonian: Miks Ulunar Breezhaler heaks kiideti?
English: For more information about treatment with Ulunar Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ulunar Breezhaleriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Ulunar Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Ulunar Breezhaleri kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It works by attaching to beta-2-adrenergic receptors found in the muscles of many organs including the airways of the lungs.
Estonian: Indakaterool on pikatoimeline β2-agonist, mis kinnitub β2-adrenergiliste retseptorite külge, mida leidub paljude elundite lihastes, sealhulgas kopsude hingamisteedes.
English: It is not intended to provide practical advice on how to use Ulunar Breezhaler.
Estonian: Hindamisaruandes ei anta Ulunar Breezhaleri kasutamise praktilisi nõuandeid.
English: This medicine is the same as Ultibro Breezhaler, which is already authorised in the European Union (EU).
Estonian: Ulunar Breezhaler on samane Ultibro Breezhaleriga, millel juba on Euroopa Liidus müügiluba.
English: The reduction in the rate of exacerbations was 10 to 12% higher with Ulunar Breezhaler than with tiotropium and glycopyrronium.
Estonian: Ulunar Breezhaleri kasutamisel harvenes ägenemine 10-12% rohkem kui tiotroopiumi ja glükopürrooniumi kasutamisel.
English: A third study investigated the effects of Ulunar Breezhaler on the rate of exacerbations (flare-ups) patients experienced during 64 weeks of treatment when compared with treatment with glycopyrronium or tiotropium (other treatments for COPD).
Estonian: Kolmas uuring hindas Ulunar Breezhaleri toimet ägenemiste sagedusele patsientidel 64 ravinädala jooksul võrreldes glükopürrooniumi või tiotroopiumiga toimuva raviga (samuti kroonilise obstruktiivse kopsuhaiguse ravimid).
English: In the second study the average increase in FEV1 was 140 ml more with Ulunar Breezhaler treatment than with treatment with fluticasone and salmeterol.
Estonian: Teises uuringus suurenes FEV1 väärtus Ulunar Breezhaleri kasutamisel keskmiselt 140 ml rohkem kui flutikasooni ja salmeterooli kasutamisel.
English: What are the risks associated with Ulunar Breezhaler?
Estonian: Mis riskid Ulunar Breezhaleriga kaasnevad?
English: While one study compared the effects of Ulunar Breezhaler with those of placebo (a dummy inhalation), or indacaterol or glycopyrronium alone, the other study compared Ulunar Breezhaler with fluticasone plus salmeterol, a standard treatment for COPD.
Estonian: Ühes uuringus võrreldi ravimit Ulunar Breezhaler platseeboga (näiv inhalaator) või eraldi manustatava indakaterooli või glükopürrooniumiga ning teises võrreldi ravimit Ulunar Breezhaler flutikasooni ja salmeterooli kombinatsiooniga, mis on kroonilise obstruktiivse kopsuhaiguse standardravi.
English: The active substances in Ulunar Breezhaler, indacaterol and glycopyrronium, work in different ways to widen the airways and improve breathing in COPD.
Estonian: Ulunar Breezhaleri toimeained indakaterool ja glükopürroonium toimivad kumbki eri viisil, laiendades hingamisteid ja soodustades kroonilise obstruktiivse kopsuhaiguse korral hingamist.
English: The recommended dose is one inhalation once a day of the powder content of a single capsule.
Estonian: Soovitatav annus on ühe kapsli pulbri üks inhalatsioon üks kord ööpäevas, iga päev samal kellaajal Ulunar Breezhaleri inhalaatori abil.
English: How is Ulunar Breezhaler used?
Estonian: Kuidas Ulunar Breezhalerit kasutatakse?
English: Muscarinic receptor antagonists and long-acting beta-2 agonists are commonly combined in the management of COPD.
Estonian: Muskariiniretseptori antagonistide ja pika toimeajaga β2-agonistide koos kasutamine on kroonilise obstruktiivse kopsuhaiguse ravis tavaline.
English: Regarding its safety, Ulunar Breezhaler is comparable to indacaterol and glycopyrronium used as separate medicines.
Estonian: Ulunar Breezhaleri ohutus on võrreldav indakaterooli ja glükopürrooniumi ohutusega nende eraldi kasutamisel.
English: When inhaled, indacaterol reaches the receptors in the airways and activates them.
Estonian: Inhaleeritud indakaterool jõuab hingamisteede retseptoriteni ja aktiveerib need, lõõgastades nii hingamisteede lihaseid.
English: Ulunar Breezhaler is available as capsules containing a powder for inhalation and can only be obtained with a prescription.
Estonian: Ulunar Breezhaler on retseptiravim ja seda turustatakse inhalatsioonipulbri kapslitena.
English: How does Ulunar Breezhaler work?
Estonian: Kuidas Ulunar Breezhaler toimib?
English: For the full list of all side effects and restrictions, see the package leaflet.
Estonian: Ulunar Breezhaleri kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What benefits of Ulunar Breezhaler have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ulunar Breezhaleri kasulikkus?
English: This summary was last updated in 1-2006 ©EMEA 2006
Estonian: Kokkuvõtte viimane uuendus: 01-2006 ©EMEA 2006
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Monotard to Novo Nordisk A/S in on 7 October 2002.
Estonian: Euroopa Komisjon väljastas Monotardi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Novo Nordisk A/S 7. oktoobril 2002.
English: They recommended that Monotard be given marketing authorisation.
Estonian: Monotardile soovitati anda müügiluba.
English: Other information about Monotard:
Estonian: Muu teave Monotardi kohta
English: Monotard is supplied as 40 or 100 IU strengths in vials.
Estonian: Monotard on saadaval viaalides, tugevusega 40 või 100 IU.
English: Monotard doses might also need to be adjusted when given with a number of other medicines which may have an effect on blood sugar (the full list is available in the Package Leaflet).
Estonian: Samuti võib osutuda vajalikuks kohandada Monotardi annust, kui seda võetakse koos mõne teise ravimiga, mis võib mõjutada veresuhkru taset (ravimite täielik loetelu on pakendi infolehel).
English: What is the risk associated with Monotard?
Estonian: Millised on Monotardiga kaasnevad riskid?
English: Monotard can be used in type 1 diabetes, when the pancreas cannot produce insulin, and in type 2 diabetes, when the body is not able to use insulin effectively.
Estonian: Monotardi saab kasutada I tüüpi suhkurtõve puhul, kui kõhunääre ei suuda toota insuliini, ja II tüüpi suhkurtõve puhul, kui organism ei suuda insuliini tõhusalt kasutada.
English: Monotard should not be used in people who may be hypersensitive (allergic) to insulin human (rDNA) or to any of the other ingredients.
Estonian: Monotardi ei tohi kasutada inimestel, kes võivad olla iniminsuliini (rDNA) või mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The Committee for Medicinal products for Human Use (CHMP) decided that Monotard's benefits are greater than its risks for the treatment of diabetes.
Estonian: Inimtervishoius kasutatavate ravimite komitee jõudis otsusele, et Monotardi kasulikkus suhkurtõve ravis on suurem kui sellega kaasnevad riskid.
English: Monotard contains the active ingredient insulin human (rDNA).
Estonian: Monotard sisaldab toimeainena iniminsuliini (rDNA).
English: Monotard contains insulin mixed with another substance, zinc, in particles from which the insulin is absorbed much more slowly during the day; and this gives Monotard a longer duration of action.
Estonian: Monotard sisaldab teise ainega, tsingiga segatud insuliini, mis moodustab osakesi, millest insuliin imendub päeva kestel palju aeglasemalt ja seepärast on Monotardi toimeaeg pikem.
English: Monotard has been studied in both type 1 and type 2 diabetes, and it has been compared to other types of insulin (porcine, human).
Estonian: Monotardi uuriti nii I kui II tüüpi suhkurtõvega patsientidel ja seda võrreldi muude insuliini liikidega (seainsuliin, iniminsuliin).
English: Monotard is used in patients with diabetes mellitus.
Estonian: Monotardi kasutatakse suhkurtõvega patsientidel.
English: Monotard is a long-acting insulin, it can be given as a once daily or twice daily injection, with or without a fast-acting insulin (at meal times), according to the doctor's recommendation.
Estonian: Seda saab süstida üks või kaks korda päevas, kas koos kiiretoimelise insuliiniga (söögiaegadel) või ilma, toimides vastavalt arsti soovitusele.
English: Monotard may cause hypoglycaemia (low blood sugar).
Estonian: Monotard võib põhjustada hüpoglükeemiat (veresuhkru madalat taset).
English: Why has Monotard been approved?
Estonian: Miks Monotard heaks kiideti?
English: Monotard was effective for both Type 1 and Type 2 diabetes.
Estonian: Monotard oli tõhus nii I kui II tüüpi suhkurtõve puhul.
English: Monotard led to a decrease in the level of HbA1c, indicating that blood sugar levels had been controlled to a similar level to that seen with other human insulin.
Estonian: Monotard vähendas HbA1c sisaldust, mis näitas, et organism reguleeris veresuhkru sisaldust samamoodi kui muu iniminsuliini korral.
English: What is Monotard?
Estonian: Mis on Monotard?
English: Monotard is given subcutaneously (under the skin) by injection, usually in the thigh.
Estonian: Monotardi manustatakse subkutaanse (nahaaluse) süstena, tavaliselt reide.
English: For the full description of the side effects reported with Monotard, please see the Package Leaflet.
Estonian: Monotardi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: What benefit has Monotard shown during the studies?
Estonian: Milles seisneb uuringute põhjal Monotardi kasulikkus?
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) MONOTARD EPAR summary for the public
Estonian: MONOTARD Kokkuvõte üldsusele
English: How has Monotard been studied?
Estonian: Kuidas Monotardi uuriti?
English: How is Monotard used?
Estonian: Kuidas Monotardi kasutatakse?
English: Monotard is a replacement insulin which identical to the insulin made by the pancreas .The active ingredient of Monotard, insulin human (rDNA), is produced by a method known as ‘recombinant technology'.
Estonian: Monotardi toimeainet iniminsuliini (rDNA) toodetakse rekombinatsioonitehnoloogiaks nimetataval meetodil.
English: The full EPAR for Monotard is available here.
Estonian: Monotardi Euroopa avaliku hindamisaruande täisteksti leiate siit.